This document is authorized for educator review use only by Gregory Theyel, California State University – East Bay until May 2018. Copying or posting is an infringement of copyright.

This document is authorized for educator review use only by Gregory Theyel, California State University – East Bay until May 2018. Copying or posting is an infringement of copyright.

Exhibit 2 Company Milestones

1996 Merger of Ciba-Geigy and Sandoz to create one of the largest healthcare companies

2002 Novartis Institutes for Biomedical Research (NIBR) is created, headquartered in the United States

2003 Acquisition of Mead Johnson & Co., a subsidiary of Bristol-Myers Squibb

2004 Novartis submits Xolair for EU approval for treatment of allergic asthma

NIBR announces joint project with the Broad Institute of MIT and Harvard to research type 2 diabetes

2005 Landmark trial on Gleevec/Glivec, to treat chronic myeloid leukemia, shows 90% of patients still alive after four years of treatment

Aclasta gains EU regulation approval for treatment of Paget’s bone disease

Acquired North American over the counter brand portfolio of Bristol-Myers Squibb, expanding Novartis’ presence

2006 Strategic biomedical R&D center opens in Shanghai

Novartis Institute for Tropical Disease (NITD) initiates research on malaria. Through partnership with World Health Organization (WHO), provides anti-malarial Coartem, for no charge in developing nations

Omnitrope receives European Commission approval; 1st product approved under the EU’s new regulatory pathway for follow-on biological products

2007 Completed non-core divestments of the Gerber and Medical Nutrition Business units to Nestlé for $5.5 billion and $2.5 billion, respectively

Ranked No. 1 among pharmaceutical companies in Fortune magazine’s “World’s Most Admired Companies” survey

2008 Novartis announced an agreement to acquire 25% interest in Alcon, Inc., world leader in eye care with pharmaceutical, surgical, and consumer products (majority ownership acquired in 2010 and 100% in 2011)

Opened new vaccine research institute in Siena, Italy

Named healthcare super sector leader in the 2008 update of the Dow Jones Sustainability World Index

2009 Novartis became the first company to produce influence A (H1N1) vaccines with modern cell-culture biotechnology

Announced $1 billion investment over five years in China to build the largest pharmaceutical R&D institute in China

2010 Joseph Jimenez was named CEO

FDA approved Gilenya as the first oral treatment for relapsing-remitting multiple sclerosis

2011 Vaccines and medicines from Novartis reach an estimated $1 billion patients

Ranked No. 1 among pharmaceutical companies in Fortune magazine’s “World’s Most Admired Companies” survey

2012 Novartis to start construction of new biotechnology facility in Singapore with an investment of over $500 million

Source: Company documents.

16

Explanation & Answer

Our website has a team of professional writers who can help you write any of your homework. They will write your papers from scratch. We also have a team of editors just to make sure all papers are of HIGH QUALITY & PLAGIARISM FREE. To make an Order you only need to click Order Now and we will direct you to our Order Page at Litessays. Then fill Our Order Form with all your assignment instructions. Select your deadline and pay for your paper. You will get it few hours before your set deadline.